Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 29.7% from a year ago
Common stock stood at $48K at the end of Q1 FY2026, up 29.7% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.7% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +29.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 48K USD
- Year-over-year change
- +29.7%
- 3-year CAGR
- +15.7%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48K | +29.7% |
| FY2024 | 2024-12-31 | 37K | +825.0% |
| FY2023 | 2023-12-31 | 4K | -87.1% |
| FY2022 | 2022-12-31 | 31K | — |
Common Stock vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 common stock of $48K is the 2nd highest of the 10 companies compared; the peer median is $5K.
- Its year-over-year change of +29.7% is the 4th highest of 9, against a peer median of +9.8%.
- Common stock amounts to 0.0% of total assets for RAPP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90K | +45.2% | +45.9% | 0.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $48K | +29.7% | +15.7% | 0.0% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $37K | +42.3% | +45.5% | 0.0% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $18K | +12.5% | +78.3% | 0.0% |
| Sep 2026 | $15K | +7.1% | +44.2% | 0.0% | |
| Jun 2026 | $5K | +0.0% | +7.7% | 0.0% | |
| Mar 2026 | $5K | — | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3K | +200.0% | +44.2% | 0.0% |
| Mar 2026 | $3K | +0.0% | +44.2% | 0.0% | |
| Sep 2026 | $0 | -100.0% | +0.0% | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $5K | +9.8% | +44.2% | 0.0% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.